# Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

> **NCT01500772** · PHASE3 · TERMINATED · sponsor: **Debiopharm International SA** · enrollment: 6 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Alisporivir
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01500772
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500772, "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01500772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*